Merck has entered a $2 billion licensing deal with China's Hansoh Pharma for an oral weight-loss drug, positioning itself ...

Merck announced a weight loss drug deal Wednesday with China-based Hansoh worth up to $2 billion for the pill code-named ...

Merck & Co. snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as $2 billion.

Merck & Co. Inc. has turned to Asia for a second time to get into the GLP-1 market, this time to Shanghai-based Hansoh ...

By licensing a drug from Hansoh, Merck signaled that it isn’t prepared to fully challenge its rivals' dominance in the GLP-1 ...

Merck threw its hat into the obesity race on Wednesday, inking a deal worth up to $2.01 billion with Hansoh Pharma for its ...

News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen ...

Merck & Co. is doubling down on getting into the white-hot weight-loss drug market, scooping up a pill developed in China. Merck said Wednesday it will pay Hansoh Pharma $112 million upfront for the ...

The Fed is widely expected to reduce interest rates by 25 basis points at its meeting. With a rate cut broadly priced in, the ...

Merck partners with Hansoh Pharma for GLP-1 drug development, while analysts highlight Viking's obesity assets as key for ...